Navigation Links
Musculoskeletal center wins $2.2 million for drug safety
Date:11/18/2008

range of autoimmune disorders. Among the studied drugs is what's called anti-TNF agents, or anti-tumor necrosis factor alpha agents. This category includes adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade). Five additional biologics will be studied.

The analysis will include patients who live in rural areas, and those who've been diagnosed with more than one autoimmune illness. Data will come from more than 100,000 biologics patients in the period 1998 to 2007.

The biologics study will include researchers from Brigham and Women's Hospital in Boston, Kaiser Permanente's Division of Research in California, Oregon Health and Science University in Portland, the University of Massachusetts Medical Center in Worcester, the University of Pennsylvania in Philadelphia and Vanderbilt University in Nashville.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Georgia Tech/Emory Center to study origin of life
2. Woods Hole Research Center to lead undergraduate initiative in the Siberian Arctic
3. $10 million gift to support cutting-edge epigenome center at USC
4. 3 Columbia University Medical Center faculty elected to Institute of Medicine
5. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
6. NYUs Center for Genomics & Systems Biology receives $4.4 million NSF grant
7. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
8. Woods Hole Research Center debuts new image mosaic that will strengthen global forest monitoring
9. DFG to establish 10 new collaborative research centers
10. Ireland Cancer Center researchers advance stem cell gene therapy
11. Manomet Center awarded major NFWF grant to foster shorebird conservation
Post Your Comments:
*Name:
*Comment:
*Email: